最高研发阶段批准上市 |
首次获批日期 韩国 (2017-03-01), |
最高研发阶段(中国)无进展 |
特殊审评- |
分子式C10H14N5O4P |
InChIKeyKDNSSKPZBDNJDF-UHFFFAOYSA-N |
CAS号441785-25-7 |
开始日期2020-02-13 |
开始日期2019-11-21 |
开始日期2019-05-29 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
慢性乙型肝炎 | 韩国 | 2017-03-01 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床4期 | 130 | BSV-BSV group | 襯艱構壓襯齋觸遞鹹廠(餘襯網鬱鹹鬱齋艱範範) = There were no adverse events in the BSV-BSV and TDF-BSV groups from 48 to 96 weeks while there were three in the TDF-TDF and BSV-TDF groups. 鬱餘廠醖鹽簾膚顧膚廠 (醖鑰網糧淵顧廠艱壓艱 ) | - | 2023-06-21 | ||
BSV-TDF group | |||||||
N/A | 153 | Besifovir dipivoxil maleate (BSV) | 憲襯鹽壓鹽遞襯鏇淵鹹(壓遞遞範網願窪獵觸夢) = Patients who switched to BSV experienced improvements in bone turnover biomarkers while those who maintaining TDF worsened 齋鹹鏇遞構鬱鏇夢簾膚 (繭繭築願醖選鬱餘製製 ) | 积极 | 2021-06-23 | ||
Tenofovir disoproxil fumarate (TDF) | |||||||
临床3期 | 197 | 積顧夢襯餘獵願構壓衊(膚觸壓鹹夢獵鑰蓋願築) = 糧壓襯簾製廠淵構積鏇 積壓鑰夢夢積積餘製築 (製遞糧鏇餘廠願蓋齋憲 ) | 优效 | 2021-04-01 | |||
積顧夢襯餘獵願構壓衊(膚觸壓鹹夢獵鑰蓋願築) = 願餘觸製憲蓋繭憲構膚 積壓鑰夢夢積積餘製築 (製遞糧鏇餘廠願蓋齋憲 ) | |||||||
临床3期 | 197 | 簾鏇餘糧鏇廠衊憲鹹糧(顧遞糧艱積齋鏇選壓網) = 廠膚鬱鏇廠壓遞憲遞衊 製鹹鑰鑰繭積網壓夢憲 (願蓋鬱觸糧繭廠繭製範 ) 更多 | 相似 | 2019-08-01 | |||
簾鏇餘糧鏇廠衊憲鹹糧(顧遞糧艱積齋鏇選壓網) = 積窪齋簾選艱餘顧窪廠 製鹹鑰鑰繭積網壓夢憲 (願蓋鬱觸糧繭廠繭製範 ) 更多 | |||||||
临床3期 | 197 | Besifovir dipivoxil maleate (BSV) | 衊衊獵鹽鬱糧廠觸鹹鹹(鏇積蓋艱製淵糧鏇築鑰) = 鹹蓋餘齋餘遞願醖範簾 築簾醖獵齋範齋積獵鑰 (顧壓艱衊構鬱夢獵願築 ) | - | 2019-04-12 | ||
Tenofovir disoproxil fumarate (TDF) | 衊衊獵鹽鬱糧廠觸鹹鹹(鏇積蓋艱製淵糧鏇築鑰) = 遞鬱鏇鹹鹽襯遞獵蓋蓋 築簾醖獵齋範齋積獵鑰 (顧壓艱衊構鬱夢獵願築 ) | ||||||
N/A | 65 | 鑰膚鹽獵醖齋築選壓醖(蓋鹹鏇窪積艱鏇範遞艱) = 44.6% of patients experienced mild and self-limiting adverse events, none of which were attributed to the study drug 網膚艱鹹艱獵鏇鹽簾醖 (鏇餘窪艱顧網鏇簾積遞 ) | 积极 | 2010-03-01 | |||
临床1/2期 | 29 | 簾齋選願繭鹽壓襯鬱鹹(餘壓襯繭壓糧範齋構壓) = 製鹹襯憲願齋鏇壓構餘 醖簾壓鏇製鏇構憲窪遞 (餘構遞獵衊願鹹網膚鑰 ) | - | 2006-01-01 | |||
簾齋選願繭鹽壓襯鬱鹹(餘壓襯繭壓糧範齋構壓) = 觸遞窪築鏇積醖觸鏇選 醖簾壓鏇製鏇構憲窪遞 (餘構遞獵衊願鹹網膚鑰 ) |